NVO NOVO NORDISK A S

NYSE novonordisk.com


$ 48.36 $ 0.00 (0 %)    

Tuesday, 04-Nov-2025 08:04:02 EST
QQQ $ 623.82 $ 0.00 (0 %)
DIA $ 470.61 $ 0.00 (0 %)
SPY $ 676.65 $ 0.00 (0 %)
TLT $ 89.78 $ 0.00 (0 %)
GLD $ 366.80 $ 0.00 (0 %)
$ 49.11
$ 49.43
$ 48.35 x 400
$ 48.38 x 120
-- - --
$ 44.55 - $ 109.43
11,146,996
na
221.49B
$ 0.75
$ 15.80
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

 - Reuters Citing Court Filing

 hims--hers-stock-pops-after-q3-earnings-heres-why

Here's a look at the Q3 earnings report from Hims & Hers Health.

Core News & Articles

Discussions with Novo NordiskHims & Hers and Novo Nordisk are in active discussions to make Wegovy injections and Novo Nord...

Core News & Articles

- Reuters

Core News & Articles

- Reuters

 pfizer-accuses-novo-nordisk-of-antitrust-violations-in-metsera-takeover-battle

Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challeng...

Core News & Articles

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo No...

Core News & Articles

-Reuters

Core News & Articles

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. i...

 eli-lilly-extends-lead-in-150b-obesity-drug-race-as-novo-pfizer-clash--heres-how-etfs-stand-to-gain

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the...

Core News & Articles

https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid

 pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-as-reckless

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and pot...

Core News & Articles

- Reuters 

Core News & Articles

Pfizer Inc. (NYSE:PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE:NVO) to acquire Metsera, I...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION